Massive Bio Unveils Groundbreaking Oncology/Hematology AI Platform at ASCO 2024: Revolutionizing Oncology/Hematology with AI Driven Personalized Insights for Clinical Trial Accessibility
View the full release here: https://www.businesswire.com/news/home/20240507335842/en/
- View the full release here: https://www.businesswire.com/news/home/20240507335842/en/
Selin Kurnaz, PhD, CEO of Massive Bio, states, “At Massive Bio, our mission transcends traditional clinical trial matching. - With our AI-driven system, we’re not just facilitating connections; we’re revolutionizing how oncologists/hematologists, patients, and trials interact.
- “Join us in advancing the future of oncology, where AI empowers more precise, efficient, and patient-centric clinical practices,” encourages Dr. Kurnaz.
- Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.